FEP Medical Policy Manual

FEP 2.04.07 Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance

Effective Policy Date: April 1 2021
Original Policy Date: December 2011

Related Policies:
None

Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance

Description

The diagnosis of bladder cancer is generally made by cystoscopy and biopsy. Bladder cancer has a very high frequency of recurrence and therefore follow-up cystoscopy, along with urine cytology, is done periodically to identify recurrence early. Urine biomarkers that might be used to supplement or supplant these tests have been actively investigated.

OBJECTIVE

The objective of this evidence review is to evaluate whether the diagnostic use of urinary tumor markers improves the net health outcome for patients with suspected or history of bladder cancer or for the screening of asymptomatic patients for bladder cancer or colonic polyps.

POLICY STATEMENT

The use of urinary tumor markers is considered not medically necessary in the screening, diagnosis of, and monitoring for bladder cancer, or screening for precancerous colonic polyps.
POLICY GUIDELINES

None

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

Table 1 lists urinary tumor marker tests approved or cleared for marketing by the FDA. The FDA approved or cleared tests are indicated as adjuncts to standard procedures for use in the initial diagnosis of bladder cancer or surveillance of bladder cancer patients.

Table 1. FDA Approved or -Cleared Urinary Tumor Marker Tests

<table>
<thead>
<tr>
<th>Test</th>
<th>Manufacturer</th>
<th>Type</th>
<th>Detection</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTA stat</td>
<td>Polymedco</td>
<td>Point of care immunoassay</td>
<td>Human complement factor H-related protein</td>
<td>Qualitative detection of bladder tumor-associated antigen in the urine of persons diagnosed with bladder cancer (FDA 510k cleared)</td>
</tr>
<tr>
<td>BTA TRAK</td>
<td>Polymedco</td>
<td>Reference laboratory immunoassay</td>
<td>Human complement factor H-related protein</td>
<td>Quantitative detection of bladder tumor-associated antigen in the urine of persons diagnosed with bladder cancer (FDA 510k cleared)</td>
</tr>
<tr>
<td>Alere NMP22</td>
<td>Alere</td>
<td>Immunoassay</td>
<td>NMP22 protein</td>
<td>in vitro quantitative determination of the nuclear mitotic apparatus protein (NuMA) in stabilized voided urine. Used as adjunct to cystoscopy (FDA Premarket Approval (PMA))</td>
</tr>
<tr>
<td>BladderChek</td>
<td>Alere</td>
<td>Point of care immunoassay</td>
<td>NMP22 protein</td>
<td>Adjunct to cystoscopy in patients at risk for bladder cancer (FDA PMA)</td>
</tr>
<tr>
<td>UroVysion</td>
<td>Abbott Molecular</td>
<td>FISH⁴</td>
<td>Cell-based chromosomal abnormalities</td>
<td>Aid in the initial diagnosis of bladder cancer (P030052) and monitoring patients with previously diagnosed bladder cancer (K033982) (FDA PMA and 510k)</td>
</tr>
</tbody>
</table>

FDA: U.S. Food and Drug Administration; FISH: fluorescence in situ hybridization; NMP: nuclear matrix protein.

⁴ FISH is a molecular cytogenetic technology that can be used with either DNA or RNA probes to detect chromosomal abnormalities. DNA FISH probe technology involves the creation of short sequences of fluorescently labeled, single-strand DNA probes that match target sequences. The probes bind to complementary strands of DNA, allowing for identification of the location of the chromosomes targeted.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Urine-based tests are available under the auspices of CLIA. Laboratories that offer laboratory-developed tests must be licensed by CLIA for high-complexity testing. To date, the FDA has chosen not to require any regulatory review of these tests. Laboratory-developed tests include:

- Cxbladder Monitor (Pacific Edge) measures the expression of 5 genes (MDK, HOXA13, CDC2, IGFBP5, CXCR2). Pacific Edge also has Cxbladder Detect and Cxbladder Triage tests.
- Xpert Bladder Cancer Monitor (Cepheid) measures mRNA (ABL1, CRH, IGF2, UPK1B, ANXA10) in voided urine by rtPCR.
- PolypDx™ (Metabolomic Technologies) is a urine metabolite assay that uses liquid chromatography-mass spectrometry. An algorithm compares urine metabolite concentrations to determine the likelihood of colonic adenomatous polyps.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
For individuals who have signs and/or symptoms of bladder cancer who receive urinary tumor marker tests in addition to cystoscopy, the evidence includes a number of diagnostic accuracy studies and meta-analyses of these studies. Relevant outcomes are overall survival (OS), disease-specific survival, test accuracy and validity, and resource utilization. A meta-analysis of diagnostic accuracy studies determined that urinary tumor marker tests have a sensitivity ranging from 47% to 85% and specificity ranging from 53% to 95%. This analysis found that combining urinary tumor markers with cytology improves diagnostic accuracy, but about 10% of cancers would still be missed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

For individuals who have a history of bladder cancer who receive urinary tumor marker tests in addition to cystoscopy, the evidence includes a number of diagnostic accuracy studies, meta-analyses, as well as a decision curve analysis and a retrospective study examining the clinical utility of urinary tumor marker tests. Relevant outcomes are OS, disease-specific survival, test accuracy and validity, and resource utilization. The diagnostic accuracy studies found that urinary tumor marker tests have pooled sensitivity ranging from 46% to 84% and pooled specificity ranging from 71% to 91%. The decision analysis found only a small clinical benefit for use of a urinary tumor marker test and the retrospective study found that a urinary tumor marker test was not significantly associated with findings of the subsequent surveillance cystoscopy. No studies using the preferred trial design to evaluate clinical utility were identified; ie, controlled studies prospectively evaluating health outcomes in patients managed with and without the use of urinary tests or prospective studies comparing different cystoscopy protocols used in conjunction with urinary tumor markers. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

For individuals who are asymptomatic and at a population-level risk of bladder cancer who receive urinary tumor marker tests, the evidence includes a systematic review and several uncontrolled prospective and retrospective studies. Relevant outcomes are OS, disease-specific survival, and test accuracy and validity. A 2010 systematic review (conducted for the U.S. Preventive Services Task Force) did not identify any randomized controlled trials, the preferred trial design to evaluate the impact of population-based screening and found only 1 prospective study that the Task Force rated as poor quality. A more recent retrospective study, assessing a population-based screening program in the Netherlands, reported low diagnostic yield. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

For individuals who are asymptomatic and at a population-level risk of colon cancer who receive urinary tests for precancerous polyps, the evidence includes a validation study. Relevant outcomes are OS, disease-specific survival, and test accuracy and validity. The clinical data supporting a urine metabolite assay for adenomatous polyps includes a report of a training and validation set published in 2017. Current evidence does not support the diagnostic accuracy of urinary tumor markers to screen asymptomatic individuals for precancerous polyps. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

National Comprehensive Cancer Network

The National Comprehensive Cancer Network (v.6.2020) bladder cancer guidelines include consideration for urinary urothelial tumor markers every 3 months along with urine cytology for the first 2 years of follow-up for high-risk patients with non-muscle-invasive bladder cancer.
bladder cancer (category 2B recommendation). The guidelines include the following statement: "Many of these tests have a better sensitivity for detecting bladder cancer than urinary cytology, but specificity is lower. Considering this, evaluation of urinary urothelial tumors may be considered during surveillance of high-risk non-muscle-invasive bladder cancer. However, it remains unclear whether these tests offer additional information that is useful for detection and management of non-muscle-invasive bladder tumors."

**American Urological Association and Society of Urologic Oncology**

The guidelines from the American Urological Association and Society of Urologic Oncology (2016; amended 2020) addressed the diagnosis and treatment of non-muscle-invasive bladder cancer, based on a systematic review completed by the Agency for Health Care Research and Quality and through additional supplementation that further addressed key questions and more recently published literature. Table 2 summarizes statements on the use of urine markers after the diagnosis of bladder cancer.

Table 2. Guidelines for Urine Tumor Markers After the Diagnosis of Bladder Cancer

<table>
<thead>
<tr>
<th>Guidance Statement</th>
<th>SOR</th>
<th>LOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;In surveillance of NMIBC, a clinician should not use urinary biomarkers in place of cystoscopic evaluation.&quot;</td>
<td>Strong</td>
<td>B</td>
</tr>
<tr>
<td>&quot;In a patient with a history of low-risk cancer and a normal cystoscopy, a clinician should not routinely use a urinary biomarker or cytology during surveillance.&quot;</td>
<td>Expert opinion</td>
<td></td>
</tr>
<tr>
<td>&quot;In a patient with NMIBC, a clinician may use biomarkers to assess response to intravesical BCG (UroVysion FISH) and adjudicate equivocal cytology (UroVysion FISH and ImmunoCyt™).&quot;</td>
<td>Expert opinion</td>
<td></td>
</tr>
</tbody>
</table>


**American Urological Association/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction**

In 2020, the American Urological Association/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction published a guideline on the diagnosis, evaluation, and follow-up of microhematuria. This guideline recommended the following with regard to urinary markers:

- Clinicians should not use urine cytology or urine-based tumor markers in the initial evaluation of patients with microhematuria [Strong recommendation; Evidence level: Grade C]
- Clinicians may obtain urine cytology for patients with persistent microhematuria after a negative workup who have irritative voiding symptoms or risk factors for carcinoma in situ [Expert opinion]

**U.S. Preventive Services Task Force Recommendations**

The U.S. Preventive Services Task Force (2011) concluded that there was insufficient evidence to assess the benefits and harms of screening for bladder cancer in asymptomatic adults. The recommendation was based on insufficient evidence (grade I). In April 2019, a literature surveillance report was published that scanned for relevant literature in PubMed and PubMed databases and the Cochrane library from 2009 to present. The researchers found "no relevant systematic reviews on the impact of screening for bladder cancer on morbidity and mortality, outcomes of treatment of screen-detected bladder cancer, or harms of screening for or treatment of screen-detected bladder cancer." Additionally, "no randomized, controlled trials or controlled observational studies compared the benefits or harms of treatment of screen-detected bladder cancer with no treatment."
**Medicare National Coverage**

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

**REFERENCES**


The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
**POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2013</td>
<td>New policy</td>
<td>Policy updated with literature review, policy statement unchanged.</td>
</tr>
<tr>
<td>June 2014</td>
<td>Replace policy</td>
<td>Policy updated with literature review. Policy statement unchanged. References 4, 23, &amp; 25 added; others renumbered or removed.</td>
</tr>
<tr>
<td>October 2018</td>
<td>Replace policy</td>
<td>Policy updated with literature review through April 9, 2018; references 1, 8, 11-12, and 20 added; some references removed. Urinary bladder cancer tumor markers as an adjunct in the monitoring of bladder cancer changed from &quot;medically necessary&quot; to &quot;not medically necessary&quot;. Title changed to &quot;Urinary Biomarkers for Cancer Diagnosis and Surveillance.&quot;</td>
</tr>
<tr>
<td>March 2019</td>
<td>Replace policy</td>
<td>Policy updated with literature review through October 4, 2018; references 5-6 added. Policy statement unchanged.</td>
</tr>
<tr>
<td>March 2020</td>
<td>Replace policy</td>
<td>Policy updated with literature review through October 30, 2019; no references added. Title revised to remove &quot;screening&quot; as policy does not address due to screening benefit language. Policy statement unchanged.</td>
</tr>
<tr>
<td>March 2021</td>
<td>Replace policy</td>
<td>Policy updated with literature review through October 30, 2020; references added. Policy statement unchanged.</td>
</tr>
</tbody>
</table>

**FEP 2.04.07 Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance**

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.